These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27513300)

  • 101. Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much.
    Gale RP; Opelz G
    Leuk Res; 2017 Jun; 57():109-111. PubMed ID: 28359029
    [No Abstract]   [Full Text] [Related]  

  • 102. Enhancement of the immune response to chronic myeloid leukaemia via controlled treatment scheduling.
    Chang H; Astolfi A
    Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():3889-92. PubMed ID: 19963607
    [TBL] [Abstract][Full Text] [Related]  

  • 103. How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
    Hehlmann R; Lauseker M
    Leukemia; 2024 Feb; 38(2):465-466. PubMed ID: 38218735
    [No Abstract]   [Full Text] [Related]  

  • 104. Targeted Mass Spectrometry Reveals Interferon-Dependent Eicosanoid and Fatty Acid Alterations in Chronic Myeloid Leukaemia.
    Scott HC; Draganov SD; Yu Z; Kessler BM; Pinto-Fernández A
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958498
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.
    Rath N; Olson MF
    EMBO Rep; 2012 Oct; 13(10):900-8. PubMed ID: 22964758
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Antibodies to glycosaminoglycans and cardiolipin in patients with chronic myeloid leukaemia.
    Cheng HM; Sam CK
    Br J Haematol; 1989 Aug; 72(4):594. PubMed ID: 2775663
    [No Abstract]   [Full Text] [Related]  

  • 107. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK.
    Rudolph J; Heine A; Quast T; Kolanus W; Trebicka J; Brossart P; Wolf D
    Leukemia; 2016 Oct; 30(10):2119-2123. PubMed ID: 27220666
    [No Abstract]   [Full Text] [Related]  

  • 108. Immune reconstitution and remission in CML.
    Scheinberg DA
    Blood; 2017 Mar; 129(9):1064-1065. PubMed ID: 28254822
    [No Abstract]   [Full Text] [Related]  

  • 109. Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment.
    Humlová Z; Klamová H; Janatková I; Sandová P; Sterzl I; Sobotková E; Hamsíková E; Haskovec C; Písacka M; Cetkovský P; Michalová K; Faber E; Hermanová Z; Ordeltová M; Roubalová K; Roth Z; Vonka V
    Folia Biol (Praha); 2006; 52(3):47-58. PubMed ID: 17089915
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives.
    Hewison A; Roman E; Smith A; McCaughan D; Sheridan R; Patmore R; Atkin K; Howell D
    Eur J Oncol Nurs; 2023 Dec; 67():102421. PubMed ID: 37804754
    [TBL] [Abstract][Full Text] [Related]  

  • 111. [Use of the stimulants of nonspecific resistance in the complex treatment of infectious complications in patients with chronic myeloid leukemia].
    Guseva SA
    Gematol Transfuziol; 1991 Aug; 36(8):21-3. PubMed ID: 1721597
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Integrate Imaging Flow Cytometry and Transcriptomic Profiling to Evaluate Altered Endocytic CD1d Trafficking.
    Sharma M; Zhang X; Huang S
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30417862
    [TBL] [Abstract][Full Text] [Related]  

  • 113. ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity.
    Upshaw JN; Travers R; Jaffe IZ
    JACC CardioOncol; 2022 Sep; 4(3):384-386. PubMed ID: 36213362
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Does receptor-'Ck' deficiency initiate leukaemia?
    Kaul D; Singh J
    Cancer Lett; 1997 Jan; 112(2):199-202. PubMed ID: 9066728
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Blood dendritic cells: "canary in the coal mine" to predict chronic inflammatory disease?
    Miles B; Abdel-Ghaffar KA; Gamal AY; Baban B; Cutler CW
    Front Microbiol; 2014; 5():6. PubMed ID: 24478766
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Dr. Goodhue's Address before the Rock River Medical Society.
    Ill Indiana Med Surg J; 1846 Aug; 1(3):260-262. PubMed ID: 37262497
    [No Abstract]   [Full Text] [Related]  

  • 117. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 118. MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis.
    Choi J; Kim YK; Park K; Nah J; Yoon SS; Kim DW; Kim VN; Seong RH
    Blood; 2016 Oct; 128(17):2117-2129. PubMed ID: 27605510
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia.
    Fu S; Hu Y; Fu Y; Chen F; Liu X; Zhang M; Wang X; Tu S; Zhang J
    Cancer Biol Ther; 2016 Oct; 17(10):1003-1009. PubMed ID: 27611742
    [TBL] [Abstract][Full Text] [Related]  

  • 120. ROCK inhibitor reduces Myc-induced apoptosis and mediates immortalization of human keratinocytes.
    Dakic A; DiVito K; Fang S; Suprynowicz F; Gaur A; Li X; Palechor-Ceron N; Simic V; Choudhury S; Yu S; Simbulan-Rosenthal CM; Rosenthal D; Schlegel R; Liu X
    Oncotarget; 2016 Oct; 7(41):66740-66753. PubMed ID: 27556514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.